The procedures keep compounding. The multiple keeps contracting.
Procedures grew 17% last quarter and free cash flow nearly doubled to $2.5B in 2025 — yet ISRG trades a third below its January high, near a 52-week low, because the market is finally pricing one question: does a ~40× multiple survive the arrival of Medtronic and J&J? Four analyst lenses, three scenarios, four time horizons.
Gray line = ISRG’s actual price into today ($604 high Jan ’26 → $397 52-week low → $411.06 close); colored paths = synthesized scenario midpoints forward, probability-weighted (base 50% · bull 25% · bear 25%). Log-linear, mid-year marks. The reticle marks today. Wall Street 12-month consensus ≈ $575 (range $366–$750, “Buy/Strong Buy” from ~22 of 24 covering analysts, as of mid-June 2026).
Re-weight the scenarios
Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.
Four analyst lenses, four answers
The same fundamentals support very different conclusions depending on which framework you trust. Each lens below is a synthesized expert perspective with its own 12-month target.
The Compounder
A vastly underpenetrated market — ~9M line-of-sight procedures vs. 3.15M done in 2025 — with a razor-and-blade annuity still compounding ~17%. Da Vinci 5 is ramping fast (303 of 532 systems placed in Q4’25), cardiac clearance opened a ~160K-procedure TAM, and EBIT grew +40% in Q1. You pay up for the only proven platform.
The Cash Inflection
With the manufacturing buildout finished, capex rolled off and free cash flow nearly doubled to $2.5B in 2025 — consensus models ~$4B in 2026. A fortress balance sheet (~$9.5B net cash, ~zero debt) and a completed buyback underpin a downside floor most growth names lack. The market is sleeping on the cash.
The Short Thesis
A maturing monopoly meeting real competition at ~41× forward earnings. Medtronic’s Hugo (FDA-cleared, Dec ’25) and J&J’s Ottava (de novo filed, Jan ’26) bring deep hospital relationships; China tenders increasingly favor local robots; growth is guided down to low-teens; tariffs press the margin. The multiple has nowhere to go but down.
The Monopoly Case
Two decades of clinical data, an ~11,000-system installed base, surgeon-training lock-in, and high switching costs don’t fall to a single new entrant. Because the market is underpenetrated, Hugo and Ottava expand the category as much as they split it. Morningstar/GuruFocus peg fair value near $596; the moat is the data and the surgeon, not just the robot.
Wall Street 12-month price targets
What the sell-side expects over the next year. Bars are sorted low to high and colored by rating; the dashed line is today’s $411 — note how nearly every target sits above it.
Sell-side 12-month targets — a selection of the ~24 firms covering ISRG; the full consensus is ≈ $575, about +40% above today, with a Buy/Strong-Buy skew (~22 of 24). The dashed line marks today’s $411: only the most cautious desks (Deutsche Bank cut to $366, an HSBC-type Hold) sit at or below the current price — the rest see meaningful upside. Confirmed targets: Deutsche Bank $366 (cut Jun 2), BofA $515 (cut Jun 12), Piper Sandler $580 Overweight, Bernstein $750 (high). Other firms, ratings, and targets are representative of the published range as of mid-June 2026.
Where the incision leads
Synthesized scenario midpoints (mid-year). Returns shown vs. today’s $411.06. These are illustrative frameworks, not predictions with certainty — five-year outcomes hinge on growth durability, margins, and how much of a premium multiple the market keeps paying.
1 Year
Mid-20272 Years
Mid-20283 Years
Mid-20295 Years
Mid-2031▸ Bull case — show the assumptions & math
▸ Base case — show the assumptions & math
▸ Bear case — show the assumptions & math
Revenue, capex, free cash flow & cash ($B)
Where the money actually goes. The bull and the bear theses both live in the gap between these four bars — the FCF inflection as the buildout rolls off is the crux.
Intuitive’s asset-light engine in one view: revenue compounds ~17–21%/yr to ~$10.1B (2025), and free cash flow (olive) nearly doubled to $2.5B in 2025 as the manufacturing buildout finished and capex (clay) rolled off — the heart of the bull’s “cash inflection” thesis, with consensus near $4B in 2026. The fourth bar is shown as cash & investments (slate), not debt, because ISRG carries effectively zero financial debt and a ~$9–11B net-cash war chest — the inverse of a leveraged story. The bear’s worry: competition forces capex (new platforms, fleet/financing, price) back up and stalls the FCF ramp. Figures illustrative; 2026E from consensus.
EPS path underpinning the targets ($)
The price targets aren’t pulled from the air — each is an EPS estimate times an exit multiple. Here’s the earnings ladder the scenarios are built on.
Pro-forma (non-GAAP) diluted EPS — the figure analysts apply multiples to, and which ties to the ~41× forward P/E (Jun ’26). Gray = reported (2024 ~$6.50, 2025 ~$8.90); olive = estimates assuming growth decelerating from the mid-teens toward ~13% by 2031. The base case’s ~$18.5 of 2031 EPS at a ~34× exit multiple ≈ the $640 base-case 5-year target — this is the ladder underneath those prices. (GAAP EPS was $8.00 in 2025; GAAP runs above pro-forma because of large interest/investment income on the cash pile.) Estimates illustrative.
The business is still growing
Q1 FY26, year-over-year — read these against a stock sitting near its 52-week low.
Every line is green — procedures +17%, revenue +23%, EBITDA +30%, earnings +38% — with the newer frontier lines (Ion, da Vinci 5 placements) compounding far faster off smaller bases (clay). Yet the stock trades near its 52-week low. That gap is the bull’s entire case in one chart: the business is fine; the multiple compressed. da Vinci 5 placements shown Q4’25 YoY; some frontier figures off small bases — illustrative.
Bull vs. Bear
The entire valuation argument compresses into one disagreement: is Intuitive a durable compounder worth a premium, or a maturing monopoly about to be re-rated as competition arrives?
▲ THE BULL CASE
- Growth is intact at scale. Q1’26 procedures +17% and revenue +23% to $2.77B; FY25 procedures +18% to 3.15M; management raised 2026 procedure guidance to 13.5–15.5%.
- Profit compounds faster than revenue. Adj. EBITDA +30%, non-GAAP EPS +38%, EBIT +40% in Q1 — classic installed-base operating leverage.
- A free-cash-flow inflection. FCF nearly doubled to $2.5B in 2025 (from $1.3B) as the buildout capex rolled off; consensus sees ~$4B in 2026.
- Fortress balance sheet. ~$9.5B cash & investments, effectively zero financial debt; total liabilities just $2.5B against $20.5B of assets.
- Underpenetrated TAM. Line-of-sight opportunity grew from 7M (2024) to 9M (2026) procedures; da Vinci 5 cardiac clearance (Jan ’26) opens a ~160K-procedure market that did just 17K in 2025.
- The lead is widening. 303 of 532 systems placed in Q4’25 were da Vinci 5, with higher utilization, force feedback, and 100+ feature updates.
- The reset already happened. Down ~32% from the high while earnings grew — the multiple fell from ~75× to ~51× trailing; consensus still sees ~+40% to ~$575.
▼ THE BEAR CASE
- The premium multiple is the risk. Even at ~41× forward, ISRG prices years of flawless compounding; a drift toward the med-tech average (~20×) is most of the downside even if the business is fine.
- Two giants finally arrived. Medtronic’s Hugo (FDA-cleared in urology, Dec ’25) and J&J’s Ottava (FDA de novo filed, Jan ’26) bring deep hospital relationships and broad portfolios to a long-unchallenged monopoly.
- China & OUS pressure. Provincial tenders increasingly favor local robots, win-rates fell in Q4, and limited quota slots remain — threatening the international growth in the model.
- Growth decelerates by design. 2026 da Vinci procedure guidance of 13–15% is below 2025’s 18%; any further slip breaks the compounding narrative.
- Margins under pressure. Tariffs and higher input costs pushed gross-margin guidance around; 2025 gross margin already slipped to 66% from 67.5%.
- New wild card. OpenAI’s late-May move into robotics stoked fears a deep-pocketed AI entrant could one day target surgical robotics; FDA recalls add regulatory noise.
- Sentiment is rolling over. Insiders have been selling and several desks cut targets in June (Deutsche Bank to $366, BofA to $515) even as the business looks healthy.
Risk map — likelihood × impact
Where each risk sits, not just how big it is. The hot upper-right corner — likely and high-impact — is the one that matters; for ISRG it’s the multiple itself, with the competitive threats one row down in “possible.”
- Tariffs / input costs
- China & OUS pricing
- Reimbursement / budgets
- Multiple compression
- FDA recalls / scrutiny
- Competitive R&D spend
- Hugo / Ottava share loss
- Procedure-growth slowdown
- AI-giant entry / Dv5 safety shock
Multiple compression
The ~41× forward multiple normalizes toward the med-tech average as growth matures — the single largest source of downside even if the business executes.
Hugo / Ottava share loss
Medtronic and J&J convert deep hospital relationships into system placements, pressuring ISRG’s pricing and slowing installed-base growth.
Procedure-growth slowdown
Worldwide procedure growth slips below the 13–15% guide, breaking the recurring-revenue compounding the whole thesis rests on.
China & OUS pricing
Provincial tenders favor local robots and win-rates fall, capping the international growth that underpins the long-run revenue CAGR.
Reimbursement / budgets
Tighter hospital capital budgets and cost-effectiveness scrutiny slow system purchases and elective-procedure volume.
AI-giant / safety shock
A deep-pocketed tech entrant (OpenAI-style robotics) or a da Vinci 5 safety event reprices the category overnight — low odds, high consequence.
FDA recalls / scrutiny
Recalls or heightened FDA attention on da Vinci / Ion dent the safety reputation that anchors switching costs.
Competitive R&D spend
Defending the lead (Dv5 updates, digital/AI, force feedback) raises operating spend and could pressure the margin trajectory.
Tariffs / input costs
Tariffs and higher component costs compress the ~66% gross margin management already guided lower.
The jargon, decoded
Hover the dotted terms in the metrics, or scan the desk’s working definitions here.
- Installed base
- The cumulative number of da Vinci (and Ion) systems in the field — ~11,000+ da Vinci. Each one is a recurring-revenue annuity that fires every time it’s used.
- Recurring revenue (I&A)
- Instruments & accessories plus service — ~75% of revenue. The razor-and-blade engine: place a system once, sell consumables on every procedure for years.
- Procedure volume
- The number of surgeries performed on the installed base — the core demand signal that drives consumables revenue. 3.15M da Vinci procedures in 2025.
- Utilization
- Procedures per system per year. Rising utilization (da Vinci 5 runs ahead of Xi) means each placed system earns more — pure operating leverage.
- Free cash flow
- Cash left after running and investing in the business — ~$2.5B in 2025, the fuel for buybacks and M&A. With the buildout done, capex fell and FCF inflected.
- FCF yield
- Free cash flow ÷ market cap. ~1.7% here — low, because ISRG is priced as a premium compounder, not a value name.
- EV / EBITDA
- Enterprise value (market cap minus net cash) over core operating profit. ~37× trailing here — ISRG’s net cash makes EV a bit below market cap.
- Exit multiple
- The P/E assumed at the end of the forecast. Multiply it by projected EPS to get a target price — the swing factor between the bull (~38×) and bear (~20×).
- de novo / 510(k)
- FDA pathways for novel (de novo) or substantially-equivalent (510k) devices. How rivals like Ottava and Hugo win clearance to compete.
- Prob-weighted
- Each scenario’s price × its probability, summed into a single expected value across bear, base and bull.